自体巨噬细胞治疗肝硬化:一项2期开放标签随机对照试验
这项多中心、开放标签、平行组2期随机对照试验纳入51例代偿期肝硬化且MELD评分≥10且≤17的成人患者,比较自体单核细胞来源巨噬细胞治疗(n=27)与标准医疗护理(n=24)。主要终点第90天MELD评分变化组间差异未达统计学显著(ΔΔMELD为-0.87,95%CI:-1.79,0.0;P=0.06)。随访360天内治疗组无肝脏相关严重不良事件或死亡,对照组有5例发生10起严重不良事件、3例死亡。
要点
- 主要终点未达到:第90天ΔΔMELD为-0.87(95%CI:-1.79,0.0;P=0.06)。
- 360天随访中治疗组无肝脏相关严重不良事件或死亡,对照组有5例发生10起严重不良事件、3例死亡。
- 生物标志物与健康相关生活质量未见差异,探索性分析显示巨噬细胞输注后出现抗炎血清细胞因子谱。
核心结论
- 本研究强化了巨噬细胞治疗在肝硬化中的安全性和潜在疗效,支持进一步研究。
研究设计与样本
- 多中心、开放标签、平行组2期随机对照试验(ISRCTN10368050),纳入51例代偿期肝硬化且MELD评分≥10且≤17的成人患者。
- 患者分为自体单核细胞来源巨噬细胞治疗组(n=27)与标准医疗护理对照组(n=24)。
主要发现
- 主要终点第0天至第90天MELD评分变化组间差异(ΔΔMELD)为-0.87(95%置信区间:-1.79,0.0;P=0.06),主要终点未达到。
- 360天随访期间,对照组24例中5例共发生10起严重不良事件(4起肝脏相关)和3例死亡(2例肝脏相关),治疗组无肝脏相关严重不良事件或死亡。
- 生物标志物或健康相关生活质量未见差异,探索性分析显示巨噬细胞输注后出现抗炎血清细胞因子谱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cirrhosis is a major cause of morbidity and mortality; however, there are no approved therapies except orthotopic liver transplantation. Preclinical studies showed that bone-marrow-derived macrophage injections reduce inflammation, resolve fibrosis and stimulate liver regeneration. In a multicenter, open-label, parallel-group, phase 2 randomized controlled trial ( ISRCTN10368050 ) in n = 51 adult patients with compensated cirrhosis and Model for End-Stage Liver Disease (MELD) score ≥10 and ≤17, we evaluated the efficacy of autologous monocyte-derived macrophage therapy (n = 27) compared to standard medical care (n = 24). The primary endpoint was the difference in baseline to day 90 change in MELD score (ΔMELD) between treatment and control groups (ΔΔMELD). Secondary endpoints included adverse clinical outcomes, non-invasive fibrosis biomarkers and health-related quality of life (HRQoL) at 90 d, 180 d and 360 d. The ΔΔMELD between day 0 and day 90 in the treatment group compared to controls was -0.87 (95% confidence interval: -1.79, 0.0; P = 0.06); therefore, the primary endpoint was not met. During 360-d follow-up, five of 24 participants in the control group developed a total of 10 severe adverse events, four of which were liver related, and three deaths (two liver related), whereas no liver-related severe adverse events or deaths occurred in the treatment group. Although no differences were observed in biomarkers or HRQoL, exploratory analysis showed anti-inflammatory serum cytokine profiles after macrophage infusion. This study reinforces the safety and potential efficacy of macrophage therapy in cirrhosis, supporting further investigation.
引用
- Brennan PN, MacMillan M, Manship T, et al. Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial. Nat Med. 2025. PMID: 39794616. doi:10.1038/s41591-024-03406-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。